Key result
Fibrates may lower atherosclerotic vascular complications as an alternative or adjunct to statins in T2D.
Answers are grounded in this paper and cite their sources.
Vascular complications associated with type 2 diabetes confer significant morbidity and mortality. Atherosclerosis develops much earlier and progresses more rapidly than in subjects without diabetes. The clustering of cardiovascular risk factors associated with type 2 diabetes is mainly responsible for accelerated atherosclerotic disease. While statins remain the primary lipid-modifying therapy, the pharmacological profile of the fibrates suggests potential as an alternative or additional treatment for reducing the risk of atherosclerotic vascular complications in type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
George Steiner (2007) conducted a review in Atherosclerosis in type 2 diabetes. Fibrate therapy vs. Statins was evaluated on Atherosclerotic vascular complications. Fibrate therapy may serve as an alternative or adjunct to statins for reducing atherosclerotic vascular complications in type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: